BioCentury
ARTICLE | Politics & Policy

VA: doctors should defer HCV treatment for some

April 18, 2014 10:45 PM UTC

The U.S. Department of Veterans Affairs recommended regimens containing Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) and Olysio simeprevir from Johnson & Johnson (NYSE:JNJ) for most HCV ...